The WHO series of organ-specific tumour classification systems is the gold standard for histological tumour typing, and compiled in the 'blue book series' . Hence, timely updates are required for each tumour entity to take into account improved knowledge of the underlying pathomechanisms and the best patient management as new targets for precision medicine become available. In May 2016, the revised WHO classification of tumours of the CNS was released 1, 2 and has already revolutionized the arena of neuro-oncology. For the first time in the blue book series of brain tumours, molecular genetic information is required for an integrated phenotypic-genotypic diagnosis 3 , including diffusely infiltrating glial and embryonal tumours. Building the capacity for molecular genetic analysis is an ongoing challenge, but many centres around the world have already implemented this patients have been stratified by molecular genetic analysis of microscopically reviewed surgical tissue, have been helpful for validating clinically meaningful patient cohorts 11, [15] [16] [17] [18] . However, this successful multidisciplinary strategy has not been developed for or systematically applied to the group of tumours known as long-term epilepsyassociated tumours (LEATs) 19 . Similarly, tumour entities for which evidence of distinct molecular-genetic signatures is lacking have fallen behind this rapidly developing process. The ever-expanding gulf between Virchow's original concept of cellular pathology (as a subjective diagnosis based on education and experience) and the evolving concept of molecular pathology (as an objective diagnosis obtained from laboratory tests) will lead to further classification of tumours according to whether or not they can be treated with a targeted therapy that is based on defined molecular alterations. Rare low-grade tumour entities often fall into the category without targeted therapies: it is difficult to recruit patients in sufficient numbers to generate meaningful survival data in reasonable time periods. Indeed, 'neuro developmental tumours' with a mixed glial and neuronal phenotype, a benign course, temporal lobe localization, and seizure onset at a young age as a major clinical symptom did not meet current WHO criteria for integrated histological and genetic classification. Such low-grade LEATs cover a large spectrum of neuropathological entities ( The WHO panel agreed on the need to acknowledge the rapid developments in neuro-oncology since the breakthrough discoveries of 1p/19q co-deletions as diagnostic, prognostic and predictive biomarker in oligodendrogliomas [5] [6] [7] [8] , followed by the discovery that hypermethylation of O6-methylguanine-DNA methyltransferase (MGMT) in glioblastomas is a predictive biomarker of treatment response to temozolomide 9, 10 , and the discovery of the Arg132His mutation in the IDH1 gene in diffuse gliomas 11, 12 , which can also be detected immunohistochemically 13, 14 . The growing number of randomized trials of treatment for brain tumours in which Abstract | Rapid developments in molecular genetic technology and research have swiftly advanced our understanding of neuro-oncology. As a consequence, the WHO invited their expert panels to revise the current classification system of brain tumours and to introduce, for the first time, a molecular genetic approach for selected tumour entities, thus setting a new gold standard in histopathology. The revised 5th edition of the 'blue book' was released in May 2016 and will have a major impact in stratifying diagnosis and treatment. However, low-grade neuroepithelial tumours that present with early-onset focal epilepsy and are mostly seen in children and young adults (previously designated as long-term epilepsy-associated neuroepithelial tumours, LEAT) lack such innovative clinicopathological and molecular genetic tools. The Neuropathology Task Force of the International League against Epilepsy will critically discuss this issue, and will offer perspectives on how to decipher and validate clinically meaningful LEAT entities using the current WHO approach that integrates clinicopathological and genetic classification systems.
and has already revolutionized the arena of neuro-oncology. For the first time in the blue book series of brain tumours, molecular genetic information is required for an integrated phenotypic-genotypic diagnosis 3 , including diffusely infiltrating glial and embryonal tumours. Building the capacity for molecular genetic analysis is an ongoing challenge, but many centres around the world have already implemented this patients have been stratified by molecular genetic analysis of microscopically reviewed surgical tissue, have been helpful for validating clinically meaningful patient cohorts 11, [15] [16] [17] [18] . However, this successful multidisciplinary strategy has not been developed for or systematically applied to the group of tumours known as long-term epilepsyassociated tumours (LEATs) 19 . Similarly, tumour entities for which evidence of distinct molecular-genetic signatures is lacking have fallen behind this rapidly developing process. The ever-expanding gulf between Virchow's original concept of cellular pathology (as a subjective diagnosis based on education and experience) and the evolving concept of molecular pathology (as an objective diagnosis obtained from laboratory tests) will lead to further classification of tumours according to whether or not they can be treated with a targeted therapy that is based on defined molecular alterations. Rare low-grade tumour entities often fall into the category without targeted therapies: it is difficult to recruit patients in sufficient numbers to generate meaningful survival data in reasonable time periods. Indeed, 'neuro developmental tumours' with a mixed glial and neuronal phenotype, a benign course, temporal lobe localization, and seizure onset at a young age as a major clinical symptom did not meet current WHO criteria for integrated histological and genetic classification. Such low-grade LEATs cover a large spectrum of neuropathological entities (TABLE 1) , and represent the second largest group of patients admitted for epilepsy surgery 20 . The International League against Epilepsy (ILAE) has charged its Commission on Diagnostic Methods and Neuropathology Task Force to address this controversial topic, and we will discuss herein conceptual benefits of an integrated phenotypic-genotypic approach to bridge the current validation gap -that is, what is old, what is new, and what is blue?
What is new? Novel tumour entities
The 2016 WHO classification includes a number of novel histopathological variants and novel tumour entities as defined by molecular genetic characterization (not new concept. The increasing availability of immunohistochemical surrogates for molecular genetic alterations 4 will also help with the practical application of the new WHO classification system.
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further discussed herein; for summary, see Supplementary information S1 (table) . As a general policy of the WHO expert panel, novel tumour entities should be introduced only when two publications from two independent laboratories have recognized their specific histopathological phenotype and/or molecular genotype. Prominent examples of novel tumour entities in the 2016 WHO classification includes the "diffuse midline glioma (WHO IV°)", which occurs mostly in children 21 and exhibits predominantly astrocytic differentiation. Diagnosis of this tumour requires demonstration of a Lys27Met mutation in either histone gene H3F3A or HIST1H3B/C (Supplementary information S1 (table)). These tumours typically do not present with seizures. Another novel tumour entity is the "multinodular and vacuolating neuronal tumour of the cerebrum", which is now recognized as a histopathological variant of gangliocytic tumours. This entity has been reported in a total of 15 adults presenting with temporal lobe epilepsy [22] [23] [24] [25] [26] . No grade has yet been assigned to this tumour, and it is unclear whether it is neoplastic or hamartomatous in nature.
Integrated diagnostics
The most important innovation in the new WHO 2016 classification is the panel of molecular genetic tests that has recently been added to the neuropathologist's armamentarium for studying and classifying
What is old?
What does 'LEAT' stand for? Throughout all editions of the WHO blue book, histopathological definitions and descriptions of the broad spectrum of LEAT variants remain incomplete (see below), thereby posing a challenge to the daily routine microscopic work-up. The remarkable history of newly introduced LEAT entities into every new WHO edition (TABLE 2) can be partially explained by increased recognition of the varied histological types. These tumours consist mostly of neuronal and mixed neuronalglial variants, as well as supratentorial low-grade gliomas. Early-onset drug-resistant epilepsy (mean age at onset <15 years) is often the major or only neurological symptom in a patient with LEAT 20, 31 . Another characteristic feature of LEATs is their predilection, relative to diffuse gliomas, for the temporal lobe. Gangliogliomas and dys embryoplastic neuroepithelial tumours (DNTs) are prominent examples of LEATs.
The term "long-term epilepsy-associated tumours" was originally introduced by the Bonn Epilepsy Centre for patients with a long history (>2 years) of drug-resistant epilepsy, for whom the intended treatment approach was epilepsy surgery 19 . Since that time, the clinical definitions of 'epilepsy' and 'drug-resistant epilepsy' have changed (REFS 32, 33) , as has the concept of epilepsy surgery as a last resort in treatment 34, 35 . brain tumours 2 , and has also helped to discover new, clinically meaningful entities 17 . The integrated histopathology report to support diagnosis should, therefore, describe not only the cellular (microscopic) composition of tumour tissue but also its molecular (genetic) signature 3 . As a prominent example, a genetically driven tumour classification now applies to all diffuse astrocytic and oligodendroglial tumours. The histological discrimination between astrocytomas, oligodendrogliomas and mixed oligo-astrocytomas has provoked longstanding controversy in attempts to decipher strict histological criteria for low-grade and high-grade subtypes 27 . It has long been recognized that the oligodendroglial component might be associated with an improved response to chemotherapy 6 , yet interobserver agreement during histological work-up of surgical brain tumour specimens remained poor 28 . To solve this ongoing controversy, the WHO now refers to isocitrate dehydrogenase (IDH) and 1p/19q co-deletion as molecular genetic markers to objectively differentiate the spectrum of histopathologically diverse gliomas into clinically meaningful subgroups. Clinical trials confirmed that IDH1-mutated gliomas are associated with a better prognosis than IDH1 wild-type gliomas 29 and that 1p/19q co-deletions are strongly associated with favourable outcomes in patients with anaplastic gliomas 27, 30 . Summary of tumours collected in adults and children at the German Neuropathology Reference Center for Epilepsy Surgery in Erlangen. More than 80% of tumours present with seizure onset before the age of 15 years, and typically localize to the temporal lobe (77%) 20 , herein designated as low-grade epilepsy-associated neuroepithelial tumours (LEATs). Early seizure onset and temporal localization separate LEAT from semi-benign and diffusely infiltrating gliomas that are also encountered in epilepsy surgery series (lower 3 rows). Tumour grading follows WHO grading, except ganglioglioma II°, which is not specified by the WHO classification, but used as clinical diagnosis ('analogue WHO II°') according to the proposal by Blumcke and Wiestler 37 , and isomorphic astrocytoma variant I°, which is analogous to WHO I° (REFS 65,66)). All values except patient numbers represent means. • Grade II Specifically, the diagnostic criteria for epilepsy (number of seizures and duration of epilepsy) are now less stringent in cases where a structural brain lesion can be identified and its localization is coherent with the clinical semiology; failure of two antiepileptic drugs is now sufficient to consider the epilepsy pharmacoresistant; and active epilepsy for >5 years is considered a predictor of negative outcome which is based on cell types, for example, astrocytic and oligodendroglial tumours, ependymal tumours, neuronal and mixed neuronal-glial tumours, embryonal tumours, meningiomas, and so forth.
Heterogeneity of LEATs
Compared with malignant gliomas, meningiomas or brain metastases, LEATs are rare, representing approximately in patients with an MRI-visible lesion in the temporal lobe, making these patients candidates for epilepsy surgery. We suggest, therefore, that the definition of LEAT is changed to 'low-grade epilepsyassociated neuroepithelial tumours' . However, this term (as well as terms such as 'epilepsoma' and 'epileptoma') does not fit in the WHO concept of a nosological tumour classification system, 2-5% of all brain tumours 36 . However, they are the second most common lesion in patients admitted for epilepsy surgery (the most common lesion is hippocampal sclerosis) 34 . The very broad histological spectrum of these neoplasms is another intriguing observation, and is attributed to their variable composition of astroglia, oligodendroglia, other clear cells and neurons, inflammatory cellular infiltrates, calcification or protein aggregation, and clarification 20, 31 . Published evidence for clinically meaningful LEAT entities and an integrated genotype-phenotype classification and grading system remains heterogeneous and controversial 20, 31, 37, 38 , and the WHO panel could not propose such a system in the revised edition in 2016. Nevertheless, with recent studies advocating adjuvant chemoradiation therapy in addition to surgery in low-grade gliomas 16 , it is becoming increasingly important that LEATs are clearly distinguishable from IDH1/2-wildtype low-grade gliomas to avoid any hazards of overtreatment 39 . Making this distinction is a challenge for the neuropathologist 39 . Improved imaging is leading to earlier surgery, before a 'long-term epilepsy-associated' tumour can be recognized as such rather than a tumour presenting with a spontaneous seizure, and piece-meal removal is performed in some cases; together with the large variety of histological appearances, this approach can result in an incorrect diagnosis as a diffuse low-grade glioma.
What is blue? Molecular genetic landscape in LEAT As histopathological classification systems will be continuously updated and revised, the WHO's current roadmap towards better understanding of carcinogenesis and personalized treatment needs to be adopted into LEAT management. It is now generally accepted and also recognized in the 2016 WHO classification that LEATs lack IDH1/2 mutations as well as 1p/19q co-deletions 11, 38, 40, 41 . Instead, molecular alterations in the RAS-RAF-MAPK and PI3K-AKT-mTOR signalling pathways seem to be prevalent in LEATs (FIG. 2) . BRAF Val600Glu mutations were most consistently reported as a genetic driver in gangliogliomas (18-56%). Its variable detection in DNTs (0-50%) [42] [43] [44] [45] [46] [47] [48] [49] [50] , however, may reflect the aforementioned difficulties in separating the two tumour entities at the microscopic level (see also REFS 42, 51) . As BRAF Val600Glu mutations have also been observed in pleomorphic xanthoastrocytomas 44 and pilocytic astrocytomas 44, 52 , their presence cannot be regarded yet as specific for a given tumour entity. Tyrosine kinase activating FGFR1 gene mutations are the prevailing type of genetic alteration in DNTs (seen in 58-82%) 42, 51 , whereas MYB/MYBL1 alterations are characteristic of angiocentric gliomas 42 , another LEAT tumour entity associated with drug-resistant epilepsy and early seizure onset 53 . A methylation-based classification from visually selected tumour to their variable patterns of papillary, rosetted, or nodular growth (FIG. 1) . Diffuse infiltration of tumour cell clusters at sites that are distant from the tumour mass is another common observation that leads to contradictory interpretation of the nature and classification of a given tumour 20, 31 . Highly variable estimates of LEAT-associated focal cortical dysplasia have been reported, and this association is another complex issue in need of , but has not been systematically applied to and validated for the entire LEAT spectrum. Use of mutation-specific antibodies, directed for example against the Val600Glu B-raf mutation 57 , can help
ILAE Task Force recommendations
Concluding from the aforementioned lack of innovation in LEATs, which is in striking contrast to that in embryonal tumours and diffuse gliomas, the ILAE Task Force recommends setting up the framework for prospective and controlled clinical studies (FIG. 3) , which are largely missing in LEAT research. Given that the majority of these tumours are rare and grow slowly, such trials will need to include multiple centres to recruit sufficient patient numbers within a reasonable time period. An additional goal should be to develop reference pathology centres and biorepositories of surgical brain specimens and matched blood samples across national borders to enable systematic molecular testing, and to keep pace with new technologies or biomarkers as they become available. Reliable assessment of the biological behaviour of a given LEAT and risk for malignant progression (which is generally reported to be low, albeit with a number of documented cases of malignant progression 59 ) also needs careful attention, as the current WHO edition did not specify atypia for all LEAT subtypes (that is, there is no WHO II° ganglioglioma). The tumour's epileptogenic potential to irritate remote cortical areas or recruit remote cortical networks is another challenging issue in need of clarification. Seizure semiology is determined by a tumour's localization within the brain, which, in the case of LEATs, to further explore the extent of cellular and genetic mosaicism 48, 50, 58 . It needs to be shown, however, whether such features also contribute to the epileptogenic phenotype. These studies need a careful design that is based on a validated histopathological classification scheme (FIG. 3) . Nature Reviews | Neurology ◀ is most often in the mesial or lateral temporal lobe 39 . However, satellite tumour cell infiltrates away from the mass lesion have been described in CD34 immunoreactive gangliogliomas 20, 37, 60 , and may compromise a successful postsurgical outcome. These clinico pathological issues should be addressed with approaches that include systematic genotype-phenotype analysis. Although such studies do not primarily aim to identify new treatment targets, they will help to provide evidence for a comprehensive and clinically meaningful clinico-pathological and genetic tumour classification scheme in the near future.
Interobserver agreement studies in LEATs ILAE's Task Force for Neuropathology was charged to address the controversial issue of interobserver agreement in LEATs and to launch an interdisciplinary agreement study for LEAT grading and classification. This Task Force has recently been successful in the implementation of international consensus classification systems for focal cortical dysplasia 61 and hippocampal sclerosis 62 in patients with drug-resistant epilepsy, and also introducing a collaborative virtual microscopy platform 63 . In a first agreement study of 30 LEATs randomly selected from a multicentre epilepsy surgery series (German Neuropathology Reference Centre for Epilepsy Surgery in Erlangen), agreement among 25 invited colleagues from 12 countries, all of whom were experienced LEAT entities. Therefore, the revised WHO classification 2016 contains no histopathological or molecular genetic advances in relation to this group of tumours. It is mandatory that WHO's view should be adapted soon so that a comprehensive clinicopathological and genetic classification system for epilepsyassociated neuroepithelial tumours can be established in the near future.
in epilepsy surgery programmes, was only 40% (R. Coras, unpublished work). Use of immuno histochemical markers, such as CD34 and MAP2 (REFS 20, 60, 64) , achieved only slightly better agreement in the same series of tumour specimens (R. Coras, unpublished work). The current situation is therefore reminiscent of that in oligodendrogliomas (as discussed above), and we should follow the WHO's molecular genetic approach to achieve a comprehensive and robust integrated classification scheme for LEATs.
Conclusions
By establishing an integrated phenotypegenotype diagnosis, the new 2016 WHO classification system has introduced a substantial change in our current neuropathological work-up. It represents a paradigm shift: microscopic inspection alone is not sufficiently reliable to predict the clinical course and treatment response in a given brain tumour. In young patients with epilepsy, a distinct subgroup of brain tumours can be encountered and is herein termed 'low-grade epilepsy-associated neuroepithelial tumours' . These tumours present with a large and often mixed phenotypic spectrum and are difficult to classify by existing schemes. Also, as reported by case series studies, the genetic alteration status of these tumours varies between individual patients. Prospective and controlled studies have not yet been performed to confirm clinically meaningful 
